search

Active clinical trials for "Syndrome"

Results 6191-6200 of 9759

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS)

This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.

Completed3 enrollment criteria

Study of Pyridoxine for Hand-Foot Syndrome

Hand-foot Syndrome

Although pyridoxine has been used empirically for the prevention of capecitabine associated hand-foot syndrome (HFS), its efficacy needs to be demonstrated in prospective controlled trials. The investigators therefore performed a prospective randomized double-blind study to determine whether pyridoxine 200 mg/day can prevent the development of HFS when given concurrently with capecitabine. The investigators also tested the ability of pyridoxine to treat primary occurrence of grade 2-3 HFS.

Completed13 enrollment criteria

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing...

Myelodysplastic SyndromesAnemia

The purpose of this study is to evaluate the effectiveness of PROCRIT (Epoetin alfa) 80,000 Units given once weekly or 80,000 Units given once every two weeks in anemic patients with Low- or Intermediate-1 risk Myelodysplastic Syndromes (MDS).

Withdrawn9 enrollment criteria

Botulinum Toxin for Carpal Tunnel Syndrome

Carpal Tunnel Syndrome

To compare local steroid injections to local Botulinum toxin A injection in a double-blinded study.

Withdrawn5 enrollment criteria

Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome

Metabolic Syndrome

The purpose of the study is to examine the effects of 2 commonly used diets, a Mediterranean monounsaturated fatty acid enriched (MUFA) or AHA polyunsaturated (PUFA) enriched diet combined with the VA Managing Overweight/Obesity for Veterans Everywhere (MOVE!) program so as to determine which one is superior in reducing cardiometabolic risk factors associated with Metabolic Syndrome. The risk factors considered include lipids and lipoproteins, inflammatory markers such as CRP and adiponectin, endothelium-dependent flow-mediated vasodilatation (FMD) and the postprandial lipid responses to a meal. Cardiometabolic risk factors will be determined by measuring several cardiovascular risk associated parameters including: Biochemical measurements of lipids and inflammatory markers, body composition and VO2max (Specific Objective 1, Descriptive). Postprandial response to a meal challenge and endothelial vasoreactivity (FMD) assessed by BART (Specific Objective 2, Physiological). Determination of the effects on postheparin lipases and transfer protein activity, visceral adipose tissue (VAT) and homeostasis model assessment-estimated insulin resistance (HOMA-IR) (Specific Objective 3, Mechanistic)

Completed18 enrollment criteria

Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease

Acute Coronary SyndromeAcute Myocardial Infarction

Aspirin and clopidogrel +/- heparin or thrombolytic co-therapy is well established and effective treatment for unstable cardiac patients. However, the major complication was gastrointestinal bleeding (GIB) due to peptic ulcer. In the prevention of GIB, anti-ulcer drug either H2-receptor antagonist (H2RA) and proton pump inhibitor (PPI) were commonly prescribed. There has been no prospective controlled study to compare the efficacy of these two classes of anti-ulcer drugs.

Completed11 enrollment criteria

IT-Based Training in Metabolic Syndrome

Metabolic Syndrome

Prospective, randomized, single center, controlled intervention study to investigate the effect of a systematic combined personal and IT-based training on the outcome of patients with metabolic syndrome.

Completed12 enrollment criteria

Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome

Acute Coronary Syndrome

This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar to that employed in the ARMYDA-ACS study.

Completed2 enrollment criteria

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic...

AnemiaChronic Myeloproliferative Disorders5 more

RATIONALE: Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell or bone marrow transplant may allow more chemotherapy to be given so that more cancer cells are killed. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Tacrolimus and methotrexate may stop this from happening. PURPOSE: This phase II trial is studying how well giving busulfan together with fludarabine before donor stem cell transplant works in treating patients with hematologic cancer.

Withdrawn63 enrollment criteria

Comparison Study of High Frequency Percussive Ventilation With Conventional Ventilation

Respiratory Distress SyndromeAdult2 more

This study is designed to exam the effects of early management with high frequency percussive ventilation (HFPV) on patients with lung injury. Patients at risk for Acute Respiratory Distress Syndrome (ARDS) will be enrolled and randomized to one of two groups. One group will be managed with HFPV. The second group will be managed with conventional ventilation utilizing lung protective techniques. The primary endpoint of the study is rate of ventilator associated pneumonia. We hypothesized that use of HFPV in patients at risk for the development of ARDS will decrease the rate of ventilator associated pneumonia when compared to patients managed with conventional ventilation.

Withdrawn5 enrollment criteria
1...619620621...976

Need Help? Contact our team!


We'll reach out to this number within 24 hrs